All News

vaccination.jpg

Safety of Recombinant Zoster Vaccine in Rheumatic Patients

EurekAlert!

New work presented at the 2025 annual EULAR congress in Barcelona focuses on the recombinant zoster vaccine (RZV), which contains recombinant glycoprotein E – the major target of CD4+T-cells.

Read Article
EULAR,poster

EULAR 2025 – Day 2 Report

Jack Cush, MD

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.

Read Article
Conv3.jpg

EULAR 2025 - Day 1 Report

Jack Cush, MD

Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

Read Article
GCA,woman

Secukinumab Use in Refractory Giant Cell Arteritis

Jack Cush, MD

In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab.

Read Article
labs2.jpg

HLA-B27 Testing in Practice

Jack Cush, MD

Analysis of testing for human leukocyte antigen B27 (HLA-B27) in a teaching center shows HLA-B27 testing was frequently performed by rheumatologists and nonrheumatologists for a broad spectrum of indications and primarily as a screening test. 

Read Article
Lupusfoto.jpg

Belimumab in SLE with Mucocutaneous or Vasculitis Findings

Jack Cush, MD

A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care.

Read Article
RheumNow Podcast square

Diagnosing Neuropsychiatric SLE (5.23.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com - including views on the vagus nerve, NPSLE and CAR-T mania.

Read Article
Manifestations of relapsing polychondritis @Lupusreference @RheumNow #EULAR2025 https://t.co/EuPOdKKjax

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#ClinicalPearls For #cartilage #swelling in #relapsing #polychrondritis Ask for #pics #Levamisole in #cocaine #infection - uncommon - from piercing Acute #bacterial v chronic #lymphoma #malignancy #vasculitis #Trauma Hx, duration, fever can be helpful #EULAR2025 @RheumNow https://t.co/X2b6VHYsYa

Links:

Janet Pope Janetbirdope ( View Tweet)
#Relapsing_Polychondritis Main differential diagnosis is GPA 🔺️No ANCA and no renal involvement in relapsing polychondritis @Lupusreference #EULAR2025 @RheumNow https://t.co/QUJZ3EDjj3

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Tips for Dx RP: 1. Suspect the dx and recognize chondritis. 2. Rule out mimickers 3.Tracheal involvement shows swelling>stenosis (helps ≠from GCA) 4. CV, heme, derm manifestations 🧐VEXAS. 5. biopsy not useful unless ≠ from GCA. Fantastic session by @Lupusreference https://t.co/W4DgfeRULF

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Great talk by @Lupusreference on Relapsing Polychondritis and a highlight of #EULAR2025. Do not forget about the articular presentations of relapsing polychondritis @RheumNow https://t.co/1xZY7VkX1z

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Rheumatoid vasculitis: what to look for and how to find it #EULAR2025 @AshimaMakol @RheumNow https://t.co/ZCUXgOr1dH

Links:

David Liew drdavidliew ( View Tweet)
How to treat rheumatoid vasculitis #EULAR2025 @AshimaMakol @RheumNow https://t.co/A8oqPd6bJx

Links:

David Liew drdavidliew ( View Tweet)
What kills in GCA? Greek national prospective cohort, small numbers and no doubt some channeling bias, but: Steroids (absence of DMARD use) is more of a factor than CV disease in GCA mortality. With new options, all GCA pts should be on something #EULAR2025 POS0960 @RheumNow https://t.co/Wmvf6tEvaF

Links:

David Liew drdavidliew ( View Tweet)
#ANCA #vasculitis is not created equally REVEAL cohort 588 ANCA Initial & 12 months #BVAS (activity index) mean ⬇️BVAS over 1 yr in all groups #GPA #MPA #eGPA 5yr survival not = over time ⬆️survival in eGPA & GPA vs MPA #POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS

Links:

Janet Pope Janetbirdope ( View Tweet)
Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/pG3aN3o4GZ
Dr. John Cush RheumNow ( View Tweet)
Single center study of 1538 #SLE pts found 2.2% w/ lupus mesenteric vasculitis (LMV) - 39 LMV episodes in 31 pts - 2/3 had Nausea, vomiting, diarrhea & abdominal pain (~15% peritoneal irritation) & had active Dz (renal, Skin, Heme). LMV responded to steroids & https://t.co/vXCpbiC60P
Dr. John Cush RheumNow ( View Tweet)
Belimumab in SLE with Mucocutaneous or Vasculitis Findings A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care. https://t.co/BlYWKLJPdb

Links:

Dr. John Cush RheumNow ( View Tweet)

Single center study of 1538 #SLE pts found 2.2% w/ lupus mesenteric vasculitis (LMV) - 39 LMV episodes in 31 pts - 2/3 had Nausea, vomiting, diarrhea & abdominal pain (~15% peritoneal irritation) & had active Dz (renal, Skin, Heme). LMV responded to steroids & https://t.co/AkuvCl6nG6
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×